Gritstone Bio: Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
Gritstone bio (GRTS) delivered earnings and revenue surprises of 38.46% and 66.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Read full article »
Gritstone Bio is a California-based biotechnology company that develops and commercializes immunotherapies for the treatment of cancer and infectious diseases.
Read more